Pharmacyclics

Pharmacyclics LLC
Subsidiary of AbbVie
Traded as Formerly NASDAQ: PCYC
Industry Biopharmaceutical
Founded 1991 (1991)
Founders Jonathan Sessler, Richard A. Miller[1]
Headquarters Sunnyvale, California
Area served
Worldwide
Key people
Robert Duggan, former CEO and Chairman
Parent AbbVie
Website pharmacyclics.com

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. Its primary focus is upon the development of "novel therapies for the treatment of cancer and immune-mediated diseases."[2]

Acquisition by AbbVie

In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire oncology firm Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity.[3] The merger is expected to close in mid-2015.[4]

Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."[5][6][7][8][9]

As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.[10][5]

References

This article is issued from Wikipedia - version of the 6/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.